ClinicalTrials.gg
CompletedNCT01254396Updated Feb 1, 2021Results posted

Pharmacokinetics Of Sildenafil Orally Disintegrating Tablet Formulation Given With Or Without Food.

A Phase 1 interventional study of Sildenafil and Sildenafil in Erectile Dysfunction, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Singapore. Open to male participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.

Enrollment
47th of 50
12 · median 108
Started
2010
with 2 others
Phase 1
6 of 50
none open now
Registered
34th of 50
by date
Lead sponsor
23 of 50
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 47th largest by enrollment, is one of 3 that started in 2010, is one of 6 in phase 1, and was the 34th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:

About sildenafil

sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing sildenafil in Erectile Dysfunction, or all of them as a file.
02

Study summary

This study will evaluate if an orally disintegrating tablet of sildenafil will have similar pharmacokinetic properties when given with food and without food.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • Bioavailability Food Effect Oral Dissolving Tablet (ODT)
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Otherwise healthy male subjects age 45 years or older with or without erectile dysfunction.
  • (BMI) of 17.5 to 32.5 kg/m2.
  • Signed .

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of abnormalities
  • Have baseline orthostatic hypotension
  • Positive drug screen, excessive alcohol and tobacco use
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Sildenafil ODT tablet 50 mg, Fasted

    Treatment A: Sildenafil ODT tablet 50 mg, administered without water under fasted conditions.

    Drug: Sildenafil

  • Experimental
    Sildenafil ODT tablet 50 mg, Fed

    Treatment B: Sildenafil ODT tablet 50 mg, administered without water under fed conditions.

    Drug: Sildenafil

Interventions

  • Orally Disintegrating Tablet, 50 mg, Single Dose

  • Orally Disintegrating Tablet, 50 mg, Single Dose

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose

  2. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

    Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hours (hrs) post-dose

Secondary outcomes

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose

  2. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]

    AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose

  3. Plasma Decay Half Life (t1/2)

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

    Time frame: 0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose

07

Results

Posted Feb 8, 2012
Limitations and caveats
AUC (0-t) was the intended primary outcome measure.

Participant flow

First Intervention Period
Participant flow — First Intervention Period
MilestoneSildenafil Fasted First, Then Sildenafil FedSildenafil Fed First, Then Sildenafil Fasted
Started66
Completed66
Not completed00
Washout Period (at Least 1 Day)
Participant flow — Washout Period (at Least 1 Day)
MilestoneSildenafil Fasted First, Then Sildenafil FedSildenafil Fed First, Then Sildenafil Fasted
Started66
Completed66
Not completed00
Second Intervention Period
Participant flow — Second Intervention Period
MilestoneSildenafil Fasted First, Then Sildenafil FedSildenafil Fed First, Then Sildenafil Fasted
Started66
Completed66
Not completed00

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax)
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLSildenafil 50 mg (Fasted)Sildenafil 50 mg (Fed)
Maximum Observed Plasma Concentration (Cmax)292.60 ± 93.84121.00 ± 56.92
Statistical analysis
  • Sildenafil 50 mg (Fasted) vs Sildenafil 50 mg (Fed) · Ratio of adjusted means: 41.35 · 90% CI 32.40 to 52.76
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
Reported as:
Median · hrs
Time to Reach Maximum Observed Plasma Concentration (Tmax)
hrsSildenafil 50 mg (Fasted)Sildenafil 50 mg (Fed)
Time to Reach Maximum Observed Plasma Concentration (Tmax)0.625 (0.250 to 1.500)4.000 (0.500 to 6.000)
SecondaryArea Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]

AUC (0-∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-∞). It is obtained from AUC (0-t) plus AUC (t-∞).

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]
ng*hr/mLSildenafil 50 mg (Fasted)Sildenafil 50 mg (Fed)
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)]838.60 ± 197.20804.00 ± 284.69
Statistical analysis
  • Sildenafil 50 mg (Fasted) vs Sildenafil 50 mg (Fed) · Ratio of adjusted means: 93.42 · 90% CI 80.23 to 108.78
PrimaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)

Area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration (AUClast).

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hours (hrs) post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
ng*hr/mLSildenafil 50 mg (Fasted)Sildenafil 50 mg (Fed)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)813.20 ± 186.29712.80 ± 245.58
Statistical analysis
  • Sildenafil 50 mg (Fasted) vs Sildenafil 50 mg (Fed) · Ratio of adjusted means: 87.66 · 90% CI 77.62 to 98.99
SecondaryPlasma Decay Half Life (t1/2)

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.

Time frame:
0 (pre-dose), 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 14 hrs post-dose
Reported as:
Mean · hrs
Plasma Decay Half Life (t1/2)
hrsSildenafil 50 mg (Fasted)Sildenafil 50 mg (Fed)
Plasma Decay Half Life (t1/2)3.039 ± 0.4842.503 ± 0.359

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sildenafil 50 mg (Fasted)—0/12 (0%)3/12 (25%)
Sildenafil 50 mg (Fed)—0/12 (0%)3/12 (25%)
Most frequent other events
Most frequent other events
EventSildenafil 50 mg (Fasted)Sildenafil 50 mg (Fed)
Catheter site haematomaGeneral disorders2/120/12
Nasal congestionRespiratory, thoracic and mediastinal disorders1/122/12
HeadacheNervous system disorders0/121/12
Dry throatRespiratory, thoracic and mediastinal disorders1/121/12
Dry skinSkin and subcutaneous tissue disorders1/121/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean56.6 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female0
Male12
08

Study locations

1 site
  • Pfizer Investigational Site
    Singapore, 188770, Singapore
09

References and documents

Publications

  • Damle B, Duczynski G, Jeffers BW, Crownover P, Coupe A, LaBadie RR. Pharmacokinetics of a novel orodispersible tablet of sildenafil in healthy subjects. Clin Ther. 2014 Feb 1;36(2):236-44. doi: 10.1016/j.clinthera.2013.12.010. Epub 2014 Jan 18. PubMed 24447534 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2010
First posted
Dec 6, 2010
Start
Dec 2010
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
Feb 8, 2012
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01254396
Responsible party
Sponsor
First posted
Dec 6, 2010
Start date
Dec 2010
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Feb 8, 2012
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion